Porównaj metody

	Oznaczenie hemolizy	Oznaczenie na żywo/martwo
Dziedzina	Biomateriały	Biomateriały
Rodzina	Process / pipeline	Process / pipeline
Rok powstania	1950	2000
Twórca	Clinical hematology traditions	Invitrogen/Molecular Probes
Typ	Hemolytic compatibility assay	Dual-dye viability assay
Źródło pierwotne	ASTM F756-17 (2017). Standard Practice for Assessment of Hemolytic Properties of Materials. ASTM International.	Molecular Probes (2004). LIVE/DEAD Viability/Cytotoxicity Kit user guide. Invitrogen Corporation.
Inne nazwy	RBC lysis assay, hemolytic compatibility test, hemolytic potential test	calcein-AM/propidium iodide, SYTO/PI staining, fluorescent viability stain
Pokrewne	4	4
Podsumowanie	The hemolysis assay is a standard method for evaluating the blood compatibility of biomaterials by quantifying the extent to which a material or substance damages red blood cells (RBCs) and causes hemoglobin release. Codified in standards including ASTM F756 and ISO 10993-4, the hemolysis assay is essential for regulatory approval of blood-contacting devices such as stents, catheters, artificial heart valves, and hemodialysis membranes. The assay provides a simple, quantitative measure of hemolytic potential that correlates with clinical safety.	The Live/Dead assay is a fluorescence-based method for simultaneously identifying live and dead cells using two complementary dyes. The assay combines calcein-AM (or SYTO fluorophores), which generates bright green fluorescence in living cells with intact esterase activity, with propidium iodide (PI), which produces red fluorescence in dead cells with compromised membrane integrity. Commercially developed by Molecular Probes and now part of Thermo Fisher's portfolio, the Live/Dead kit is widely used to evaluate cell viability on biomaterial scaffolds, in tissue constructs, and following drug or toxin exposure.